TEVA
Teva- Pharmaceutical Industries Ltd
$41.78-0.17%
Setup
Near pivot
Buy Zone
$43.34-$45.51
Sector
Drug Manufacturers - Specialty & Generic
Industry
Drug Manufacturers - Specialty & Generic
36
Recommendation
Avoid
Avoid
Too many CANSLIM criteria failing.
TEVA chart
Loading chart…
ADX
Weak or Absent11.7Long Term
Range →Intermediate Term
Range →Short Term
Down ↓Overall Quality36
RS Rating
92
relative strength
Fundamentals
21
Weak fund-Q
Volume Demand
68
+141% vs avg
Technical Setup
75
6/8 checks
Industry/Theme
91
Drug Manufacturers - Specialty & Generic
Trade Plan
Avoid
Entry
$43.34
Entry Zone
$43.34-$45.51
Stop / Risk
$39.87
RS Rating
92
Volume confirmed
No
Targets
$52.01 / $54.18
Breakout · IBD Setup
5 ✓ 3 ✗
Entry $43.34–$45.51Stop $39.87Target $52.01 / $54.18
Market regimeRange
Quality36
RS Rating92
Above 50-MA+6.03%
Above 200-MA+20.43%
VolumeWeak
In Buy ZoneYes
Not extendedOK
Invalidation · Close below stop
How this came together
36
MarketRange
SetupNear pivot
ConfidenceExperimental · not backtested
Fund-Q21 · Weak
StatusAvoid
Stock Data
52-Week Range23 – 43
Price % Chg YTD33.87%
Price % Chg 4wk6.64%
50-Day Avg Vol5.7 Mil
P/E Ratio70.2
Market Cap$49B
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Company Fundamentals
EPS % Chg (Qtr)-303.54%
Sales % Chg (Qtr)-1.38%
EPS Growth 5y—
Sales Growth 5y0.78%
Annual ROE9.68%
Gross Margin52.52%
Operating Margin18.83%
Net Margin4.07%
Debt / Equity2.18
Setup levels
Current price
$41.78
Pivot
$43.34
Distance to buy
-3.6%
52-week range
22.7-43.34
Trigger evidence
No active trigger evidence available.
Pattern levels: pivot 43.34
Financial health checks
0/5
Return on equity above 15%
ROE 9.68%
Net margin above 10%
Net margin 4.07%
EPS growing quarter on quarter
EPS q/q -303.54%
Sales growing quarter on quarter
Sales q/q -1.38%
Debt to equity below 1.0
D/E 2.18
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE9.68%
vs sector -12.9%
Net margin4.07%
vs sector -13.6%
Gross margin52.52%
vs sector -14.6%
EPS growth q/q-303.54%
vs sector -311.1%
Sales growth q/q-1.38%
vs sector -20.1%
Debt / equity2.18
vs sector +1.53
Business quality
21
GradeWeak
EPS rating4
P/E70.2
Market cap$49B
IndustryDrug Manufacturers - Specialty & Generic
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Fail
In Kaufzone
Pass
Nicht überextended
Pass
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-10-31
Trigger date
—
Days on list
6
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.